Cromos™ Pharma has published a white paper on the new EU clinical trial regulation (no. 536/2014) and investigator-led studies
Cromos™ Pharma has published a white paper on the new EU clinical trial regulation (no. 536/2014) and investigator-led studies We are glad to share with you our new white paper by Cromos™ Pharma’s VP, International Business & Operations Dr. Gearóid Tuohy regarding a new Clinical Trial Regulation (Regulation [EU] No 536/2014), scheduled for application this year, and its potential impact on the current imbalances in clinical trials. Please follow the link link to the
Meet Cromos Pharma’s CEO, Dr. Vlad Bogin in San Antonio, Texas at San Antonio Breast Cancer Symposium (SABCS 2016) on December 6-10, 2016
DUBLIN, IRELAND–(Marketwired – October 24, 2016) – Cromos™ Pharma, a premier regional contract research organization announced today that Dr. Gearóid Tuohy has been appointed… Dr. Tuohy will join the company’s Dublin office and will bring strategic thinking and in-depth knowledge of the international clinical trials landscape to further expand Cromos™ Pharma’s operations amidst its growing geographic presence. “Cromos™ Pharma continues to grow at a fast pace and we are very excited to see Dr. Tuohy joining our team,” said
Meet Cromos Pharma’s CEO, Dr. Vlad Bogin in San Antonio, Texas at San Antonio Breast Cancer Symposium (SABCS 2016) on December 6-10, 2016
We at Cromos Pharma are always interested in what makes a sponsor choose a certain CRO In order to get a better understanding of this question we have conducted a survey where we asked industry professionals about their vision of a “perfect CRO”. Our team would like to express sincere gratitude to all the participants of the survey whose responses we greatly appreciate. Below you can find the top-line results of

TO FIND OUT MORE

INQUIRY@CROMOSPHARMA.COM